OPG Expression on Endothelial Cells and Modulation by IL-1B, PDGF, Insulin, and Glucose

Ciriza, Carmen Pérez de; Lawrie, Allan; Varo, Nerea

doi:10.4172/2168-9652.1000179

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, it has been shown that OPG expression can be induced by glucose and insulin, and OPG itself increases the production of IL-6 and IL-8. 27 This finding confirms the fact that OPG is involved in the pathogenesis of both endothelial dysfunction and inflammation. Hyperglycemia contributes to the activation of inflammatory processes and to the pathogenesis of complications.…”

Section: Discussionsupporting

confidence: 76%

Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 76%

Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…( 145–147 ) Similarly, ECs can release osteoprotegerin (OPG) to minimize osteoclastogenesis during diabetes. ( 148 ) Moreover, multiple cytokines such as IL6, tumor necrosis factor‐alpha (TNF‐α), and interferon‐gamma (IFN‐γ) can be produced by ECs under inflammatory conditions, inducing nuclear factor kappa‐light‐chain enhancer of activated B cells (NF‐κB) signaling to regulate HSPC functions. ( 149 ) Inhibition of the endothelial NF‐κB pathway improves HSPC proliferation and hematopoietic recovery in mice following myelosuppressive injury.…”

Section: Inflammationmentioning

confidence: 99%

Bone Vasculature and Bone Marrow Vascular Niches in Health and Disease

Chen

Hendriks

Chatzis

et al. 2020

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Bone vasculature and bone marrow vascular niches supply oxygen, nutrients, and secrete angiocrine factors required for the survival, maintenance, and self-renewal of stem and progenitor cells. In the skeletal system, vasculature creates nurturing niches for bone and blood-forming stem cells. Blood vessels regulate hematopoiesis and drive bone formation during development, repair, and regeneration. Dysfunctional vascular niches induce skeletal aging, bone diseases, and hematological disorders. Recent cellular and molecular characterization of the bone marrow microenvironment has provided unprecedented insights into the complexity, heterogeneity, and functions of the bone vasculature and vascular niches. The bone vasculature is composed of distinct vessel subtypes that differentially regulate osteogenesis, hematopoiesis, and disease conditions in bones. Further, bone marrow vascular niches supporting stem cells are often complex microenvironments involving multiple different cell populations and vessel subtypes. This review provides an overview of the emerging vascular cell heterogeneity in bone and the new roles of the bone vasculature and associated vascular niches in health and disease.

show abstract

“…An ever-increasing number of researchers emphasise that OPG may not only be a marker of an unfavourable prognosis in CVDs, but may also play an important pathogenetic role in their development. It has been confirmed that OPG is present in vascular ECs and in VSMCs under basic conditions, and that its production increases significantly in these cells under the influence of various stimulating factors, such as cytokines or hormones [4,6,17,32]. In human aorta cells, it was confirmed that the production of OPG is 20-30 times higher in VSMCs than in ECs [6].…”

Section: Potential Opg Mechanisms Of Action In the Cardiovascular Systemmentioning

confidence: 87%

“…TNF-alpha and interleukin-1beta (IL-1B) are strong stimulators of OPG production in ECs and VSMCs. These cytokines can increase OPG expression 5-40-fold [4,6,32]. In ECs, OPG occurs in secretory granules, called Weibel-Palade bodies, where OPG is associated with the von Willebrand factor [4,6].…”

Section: Potential Opg Mechanisms Of Action In the Cardiovascular Systemmentioning

confidence: 99%

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases

et al. 2021

View full text Add to dashboard Cite

Osteoprotegerin (OPG) is a glycoprotein involved in the regulation of bone remodelling. OPG regulates osteoclast activity by blocking the interaction between the receptor activator of nuclear factor kappa B (RANK) and its ligand (RANKL). More and more studies confirm the relationship between OPG and cardiovascular diseases. Numerous studies have confirmed that a high plasma concentration of OPG and a low concentration of tumour necrosis factor–related apoptosis inducing ligand (TRAIL) together with a high OPG/TRAIL ratio are predictors of poor prognosis in patients with myocardial infarction. A high plasma OPG concentration and a high ratio of OPG/TRAIL in the acute myocardial infarction are a prognostic indicator of adverse left ventricular remodelling and of the development of heart failure. Ever more data indicates the participation of OPG in the regulation of the function of vascular endothelial cells and the initiation of the atherosclerotic process in the arteries. Additionally, it has been shown that TRAIL has a protective effect on blood vessels and exerts an anti-atherosclerotic effect. The mechanisms of action of both OPG and TRAIL within the cells of the vascular wall are complex and remain largely unclear. However, these mechanisms of action as well as their interaction in the local vascular environment are of great interest to researchers. This article presents the current state of knowledge on the mechanisms of action of OPG and TRAIL in the circulatory system and their role in cardiovascular diseases. Understanding these mechanisms may allow their use as a therapeutic target in cardiovascular diseases in the future.

show abstract

OPG Expression on Endothelial Cells and Modulation by IL-1B, PDGF, Insulin, and Glucose

Cited by 6 publications

References 0 publications

Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study

Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study

Bone Vasculature and Bone Marrow Vascular Niches in Health and Disease

Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases

Contact Info

Product

Resources

About